LBA17 – Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes - Harbeck, N; Rastogi, P; OʼShaughnessy, J (Ann Oncol, 2023)